In Q1 2026, three forces converged for the first time in Biotech & Pharma: an AI-designed molecule cleared the clinical efficacy threshold in a controlled human trial, the BIOSECURE Act restructured the supply chain landscape as law, and $84 billion in M&A confirmed the market had priced in the strategic value of AI-accelerated pipelines. None of this required insider access. It required reading the signals together.